Arcellx, Inc. (ACLX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Redwood City, MD, 미국. 현재 CEO는 Rami Elghandour.
ACLX 을(를) 보유 IPO 날짜 2022-02-04, 163 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $6.72B.
Arcellx, Inc. is a clinical-stage biotechnology company developing innovative immunotherapies for patients with cancer and other serious diseases. The company's lead candidate, CART-ddBCMA, is currently in Phase 1 clinical trials for relapsed or refractory multiple myeloma, while its pipeline includes ACLX-001, a dual-targeting immunotherapy combining ARC-T cells and SparX proteins, as well as additional programs targeting acute myeloid leukemia, myelodysplastic syndrome, and solid tumors. Founded in 2014 and headquartered in Gaithersburg, Maryland, Arcellx focuses on advancing next-generation cell and protein-based therapies to address unmet medical needs in oncology.
